News

The investigational human monoclonal antibody, OMS906 targets mannan-binding lectin-associated serine protease-3 (MASP-3), the main activator of the alternative pathway of the complement system. MASP-3 converts pro-complement factor D

This licence enables the least developed, low-income, lower middle-income as well as Sub-Saharan African countries to access the long-acting HIV prevention medicine. The deal will give the selected

Healthcare venture capital firm Lapam Capital, investment management firm Junson Capital and Dyee Capital have led the financing round. BridGene’s IMTAC platform combines ‘cutting-edge’ technologies including chemical proteomics,

PNI provides technologies, services, and solutions to develop lipid nanoparticle genomic medicines, while Replicate Bioscience designs and delivers srRNA immunotherapies. Under the terms of the deal, PNI will

Tezspire has been recommended as an add-on therapy for these patients whose condition is not sufficiently controlled with high dose inhaled corticosteroids besides another medicinal product for maintenance

The plant-derived small molecule, tigilanol tiglate targets various solid tumours across multiple species. The drug is being developed as an intratumoural treatment for solid tumours. It has a

This study was undertaken in ~184 subjects, who were randomised 1:1 and received either a booster dose of the vaccine or a placebo, ~six months following the primary

The funding round was led by Enavate Sciences, a portfolio company created by Patient Square Capital. The round also saw participation of Gaingels, along with other undisclosed investors.

Applying Avista’s single-cell adeno-associated virus (AAV) engineering (scAAVengr) platform technology, the partnership intends to develop intravitreal AAV capsids matching a capsid profile defined by Roche. As per the